{
  "docId": "019de075-e109-770f-8f32-3054686041b6",
  "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 38,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/5",
  "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
  "deckJsonHref": "/decks/019de075-e109-770f-8f32-3054686041b6.json",
  "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "UC MAINTENANCE REMISSION RATES (%) vs MAINTENANCE DOSING FREQUENCY (WEEKS)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e850c07c-c151-48c6-88f1-bc6417ea87fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "list",
      "text": "~1.7 million individuals are currently diagnosed with IBD in the U.S. There remain substantial unmet needs in IBD management, including: Inadequate response or loss of response to existing therapies; Side effects and safety concerns; Adherence to frequent and/or inconvenient dosing regimens",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0986b9d0-e53c-4800-bd55-923915727319",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Source: 1Crohn's and Colitis Foundation. 2Summary data for select agents that randomize patients post response to induction; data from labels, company reports. Vedolizumab approved in US as Q8W IV – Q2W SC approval pending following CRL in 2019. TL1A maintenance data not available. Orals not shown (pbo-adj maintenance remission rates): Jaks - tofacitinib (27%), upadacitinib (30% 15mg, 40% 30mg); S1Ps: ozanimod (19%); etrasimod (25% - P3 treat-through design).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91f17e1b-799f-448e-8e27-835ca5a8c339",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "077b6e92-ac62-4553-874a-faa80c1f2c7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "title",
      "text": "UNMET NEED",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c2ac2d5-af4a-4d5b-b562-9c9edba3b2ee",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "7f030522-1f47-4fb6-815d-14cad475c566",
      "evidence": "Positions current SOC against a future target to highlight a gap.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "d3d060f4-a6ef-45ba-9081-b2065408160d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1e678675-b00f-4ca4-9628-1ea0d4fbdd6f",
      "evidence": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "position": 0,
      "objective": "What are the consequences of not addressing unmet needs in IBD?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}